Immuron reports positive clinical study results in the fight against fatty liver disease
Dual-listed early-stage biotech company Immuron (ASX: IMC) has revealed keenly anticipated results for its phase 2 non-alcoholic steatohepatitis (NASH) clinical study. The primary objective of the study was to evaluate the safety and efficacy of IMM-124E.
https://smallcaps.com.au/immuron-positive-clinical-study-results-fight-fatty-liver-disease/
Filter by Year:
- Immuron and US Department of Defense look to develop silver bullet for gastro infections
- US Defense finishes latest research on Immuron’s Travelan®
- Immuron reports positive clinical study results in the fight against fatty liver disease
- Immuron's IMM-124E shows encouraging action in mid-stage NASH study; shares ahead 81%
- Immuron’s shares surge on demonstrating proof of concept for liver drug candidate
- Results in: IMC’s lead drug reduces major factor in liver inflammation
- Blockbuster Results from IMC’s NASH Liver Therapy Trials
This category is empty! Please try another category or use our search function to find what you are looking for. If you require further assistance please contact us.
